McKesson has raised its full-year adjusted earnings per share guidance, a move that comes as its share price slipped 1.2% and trailed the broader market. The stock has fallen 3.95% over the past 30 days, even after a 13.86% 90-day return and a 5.58% gain year to date, while total shareholder return stands at 18.50% over one year. The most followed narrative values McKesson at a fair value of $980.73 against a last close of $869.36, implying the stock is 11% undervalued, a view held by 61 investors. That story leans on the company's oncology ecosystem, including the US Oncology Network, PRISM and Precision Medicine Group, as a central driver of revenue mix and margin potential. Risks to the narrative include drug pricing pressure on already thin margins and higher costs and customer churn from a recent cyber incident.
McKesson CorporationMcKesson raised its full-year adjusted EPS guidance, a positive earnings/valuation event.
Cardinal Health Inc